GlassScriptPhysician profile
Mandy M Ferguson
NPI 1760754881
$5,171.55
in general payments reported to CMS, 2019-2025
41 companies · $919 in 2025
The $919 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,191 · 2022: $1,207 · 2023: $966 · 2024: $888 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,773.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $838.47 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $664.88 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $634.79 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.92 | 2021-2025 | Jardiance |
| Abbvie INC. | $385.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $184.72 | 2021-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $165.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $156.88 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $148.99 | 2022-2024 | Quviviq |
| Amarin Pharma, INC. | $148.89 | 2021-2022 | |
| Abbott Laboratories | $134.15 | 2022-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2021-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $119.27 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $107.78 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $100.74 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.